Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Maravai Lifesciences Holdings (MRVI) Enterprise Value (2020 - 2025)

Maravai Lifesciences Holdings has reported Enterprise Value over the past 6 years, most recently at -$56.6 million for Q4 2025.

  • Quarterly results put Enterprise Value at -$56.6 million for Q4 2025, up 21.29% from a year ago — trailing twelve months through Dec 2025 was -$56.6 million (up 21.29% YoY), and the annual figure for FY2025 was -$56.6 million, up 21.29%.
  • Enterprise Value for Q4 2025 was -$56.6 million at Maravai Lifesciences Holdings, up from -$57.2 million in the prior quarter.
  • Over the last five years, Enterprise Value for MRVI hit a ceiling of $379.1 million in Q1 2023 and a floor of -$310.4 million in Q3 2024.
  • Median Enterprise Value over the past 5 years was -$56.9 million (2025), compared with a mean of -$491550.0.
  • Biggest five-year swings in Enterprise Value: skyrocketed 247.04% in 2021 and later tumbled 218.38% in 2022.
  • Maravai Lifesciences Holdings' Enterprise Value stood at $229.9 million in 2021, then tumbled by 218.38% to -$272.1 million in 2022, then grew by 25.83% to -$201.8 million in 2023, then skyrocketed by 64.4% to -$71.9 million in 2024, then rose by 21.29% to -$56.6 million in 2025.
  • The last three reported values for Enterprise Value were -$56.6 million (Q4 2025), -$57.2 million (Q3 2025), and -$67.8 million (Q2 2025) per Business Quant data.